Ignite Creation Date:
2024-05-05 @ 9:30 PM
Last Modification Date:
2024-10-26 @ 10:05 AM
Study NCT ID:
NCT00895882
Status:
WITHDRAWN
Last Update Posted:
2015-10-22
First Post:
2009-05-06
Brief Title:
Study to Evaluate Different Regimens of Vaniprevir MK7009 for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients MK-7009-019WITHDRAWN
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase II Randomized Placebo-Controlled Study to Evaluate the Safety Tolerability and Efficacy of Different Regimens of MK7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Status:
WITHDRAWN
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety tolerability and efficacy of vaniprevir when administered concomitantly with pegylated interferon peg-IFN and ribavirin RBV to treat treatment-naive genotype 1 hepatitis C virus HCV-infected patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009_586 | None | None | None |